Germany is a European Leader in Cancer Research
A multi-billion-dollar deal for German company BioNTech is the latest indication of the central role Europe’s largest economy plays in attempts to cure the deadly disease.
Your company is already operating in Germany and you would now like to export worldwide?
A multi-billion-dollar deal for German company BioNTech is the latest indication of the central role Europe’s largest economy plays in attempts to cure the deadly disease.
Germany’s healthcare sector is attracting more VC investment as it enters the digital age. Electronic patient records are being rolled out and generative AI tools supporting the medical product approval process assessed.
Data on publicly insured patients will now automatically be registered electronically unless those concerned opt out.
Financing for companies in Germany rose markedly in 2024, with interest particularly strong in cancer treatments.
Join the DACH Invest MedTech event and get the latest updates from the DACH countries.
This forum explores business opportunities in the largest and most important healthtech regions in Europe.
Germany’s healthcare sector is benefiting from major investments in new gene and cell therapy research and development sites.
The pharmaceuticals and chemicals giant is investing a hefty nine-figure in a state-of-the-art facility in its home city of Darmstadt.
AbbVie is building an ultra-modern research and office facility in the western German city of Ludwigshafen.
Germany’s healthcare sector enjoyed a successful year with a resurgent biotech sector generating a quarter of new capital. New therapies are being developed for a range of autoimmune diseases and telemedicine service are on the rise.
The injectable Mounjaro that will be mass produced by Eli Lilly and Company in Germany has been cleared for use in helping people shed pounds.